A phase 1 clinical of Protollin to treat Alzheimer's disease
Latest Information Update: 14 Dec 2021
At a glance
- Drugs Protollin (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors I-MAB Biopharma; Jiangsu Nhwa Pharmaceutical
- 08 Dec 2021 According to an I-MAB Biopharma media release, this study is being conducted by Brigham and Women's Hospital.
- 08 Dec 2021 According to an I-MAB Biopharma media release, the first patient had been dosed in the study.
- 08 Dec 2021 Status changed from planning to recruiting, according to an I-MAB Biopharma media release.